Bitcoin price today: dips below $112k, near 6-wk low despite Fed cut bets
Hisham Shiblaq, the Executive Vice President and Chief Commercial Officer of PROCEPT BioRobotics Corp (NASDAQ:PRCT), recently sold a portion of his holdings in the company. According to a regulatory filing, Shiblaq sold 247 shares of common stock on March 18, 2025, at an average price of $57.06 per share. The transaction totaled approximately $14,093. The sale comes as PRCT shares have declined about 31% over the past six months, though InvestingPro data shows the company maintains strong liquidity with a current ratio of 9.07.
This sale was conducted to cover tax withholding obligations related to the vesting of Restricted Stock Units. Following this transaction, Shiblaq retains ownership of 63,133 shares of PROCEPT BioRobotics. According to InvestingPro analysis, the company currently trades at a high Price/Book multiple of 7.88, with analysts anticipating continued unprofitability this year. For deeper insights into PRCT’s valuation and 7 additional ProTips, explore the comprehensive Pro Research Report available on InvestingPro.
In other recent news, Procept BioRobotics Corp reported its fourth-quarter 2024 earnings, revealing a revenue of $68.24 million, surpassing the forecast of $66.83 million. Despite this revenue beat, the company posted an earnings per share (EPS) of -$0.35, slightly missing the expected -$0.34. Procept BioRobotics demonstrated a strong performance with a 57% year-over-year increase in Q4 revenue. The company anticipates a 43% revenue growth in 2025, projecting a full-year revenue of $320 million.
Additionally, Jefferies maintained its Hold rating on Procept BioRobotics with a price target of $77.00, following discussions with company executives. The firm noted that Procept BioRobotics management expects healthy utilization rates in fiscal year 2025. The company’s leadership expressed optimism about their competitive positioning in the treatment of benign prostatic hyperplasia and opportunities in prostate cancer. These developments reflect the company’s current standing and future expectations as understood by Jefferies.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.